title: PMA and doxorubicin decrease viability, MTT activity and expression of CD10 marker on NALM-1 leukemic cells.
abstract: PMA (10, 20 ng/ml) and doxorubicin (5-20 ng/ml) decreased the viability and MTT-activity of NALM-1 pre-B leukemic cells (3 days' treatment). Further, CD10 was downregulated, suggesting that PMA and doxorubicin induced differentiation of NALM-1 cells. However, PMA did not alter expression of B cell markers CD20 and of mIgM. In contrast to PMA, another differentiation agent ATRA did not alter CD10 expression on NALM-1 cells but affected viability after 6 days (5, 10 ng/ml). The data in this study are the first evidence that PMA and doxorubicin inhibited viability and MTT activity and induced partial differentiation, by decreasing CD10 on NALM-1 cells.
authors.affiliation: Division of Molecular Medicine, Ruder Bosković Institute, Zagreb, Croatia. kleiner@irb.hr
authors.forename: I
authors.initials: I
authors.lastname: Martin-Kleiner
authors.forename: I
authors.initials: I
authors.lastname: Svoboda-Beusan
authors.forename: J
authors.initials: J
authors.lastname: Gabrilovac
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D018951:Antigens, CD20 / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005562:Formazans / Q000378:metabolism; D006801:Humans; D007148:Immunoglobulin mu-Chains / Q000378:metabolism; D007938:Leukemia / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D015260:Neprilysin / Q000378:metabolism*; D053668:Syndecan-1 / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000031:analogs & derivatives* / Q000494:pharmacology; D013778:Tetrazolium Salts / Q000378:metabolism; D013997:Time Factors; D014212:Tretinoin / Q000494:pharmacology
chemical_list: D000903:Antibiotics, Antineoplastic; D018951:Antigens, CD20; D014408:Biomarkers, Tumor; D005562:Formazans; D007148:Immunoglobulin mu-Chains; C508241:SDC1 protein, human; D053668:Syndecan-1; D013778:Tetrazolium Salts; C079782:MTT formazan; D014212:Tretinoin; C016658:phorbolol myristate acetate; D004317:Doxorubicin; D015260:Neprilysin; D013755:Tetradecanoylphorbol Acetate